https://www.rsoncology.com/blog/rs-oncology-presents-new-drug-in-early-clinical-development-for-mesothelioma-and-lung-cancer-patient 2025-01-25 https://www.rsoncology.com/blog/rs-oncology-announces-positive-data-from-a-phase-1-clinical-trial-of-rso-021%2C-a-first-in-class-therapeutic-for-malignant-pleural-mesothelioma 2025-01-25 https://www.rsoncology.com/blog/11111 2025-01-25 https://www.rsoncology.com/blog/esmo-congress-september-2022 2025-01-25 https://www.rsoncology.com/blog/rs-oncology%2C-llc-announces-initiation-of-patient-dosing-in-phase-1%2F2-mitope-clinical-trial-of-rso-2 2025-01-25 https://www.rsoncology.com/blog/rs-oncology-data-for-novel-treatment-of-aggressive-cancers-selected-for-an-oral-presentation-at-asco-annual-meeting 2025-01-25 https://www.rsoncology.com/blog/recent-advancements-in-treating-malignant-pleural-mesothelioma%2C-and-why-localized-treatment-could-be-advantageous 2025-01-25 https://www.rsoncology.com/blog/aacr-2023%2C-rso-021%2C-a-first-in-class-treatment 2025-01-25 https://www.rsoncology.com/blog/11111 2025-01-25 https://www.rsoncology.com/blog/top-10-questions-to-ask-your-doctor-if-you-have-been-diagnosed-with-mesothelioma 2025-01-25 https://www.rsoncology.com/blog/rs-oncology-announces-first-patient-dosed-in-phase-2-clinical-study-(mitope)-investigating-rso-021-for-the-treatment-of-malignant-pleural-mesothelioma-and-metastatic-disease-to-the-lung 2025-01-25 https://www.rsoncology.com/blog/rs-oncology-to-present-translational-data-identifying-potential-biomarkers-associated-with-rso-021-anticancer-activity. 2025-01-25 https://www.rsoncology.com/blog/mesothelioma-uk 2025-01-25 https://www.rsoncology.com/blog/11111 2025-01-25